Korsana Biosciences Inc KRSA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $31.66
- Day Range
- $30.62–34.42
- 52-Week Range
- $1.05–37.48
- Bid/Ask
- $23.84 / $44.90
- Shares Outstanding
- 45.54M
- Market Cap
- $1.56B
- Volume/Avg
- 193,562 / 65,046
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Korsana Biosciences Inc is a biopharmaceutical company developing therapeutics to treat neurodegenerative diseases beginning with Alzheimer's disease (AD. The company's flagship product candidate, KRSA-028, is an anti-amyloid beta antibody that combines the proprietary Therapeutic Targeting (THETA) platform with well-validated aspects from other anti-Ab products that have achieved regulatory approval or are in late-stage clinical trials.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.korsana.com
Valuation
|
Metric
|
KRSA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
KRSA
|
|---|---|
Quick Ratio | 12.34 |
Current Ratio | 12.38 |
Interest Coverage | — |
Quick Ratio
KRSA
Profitability
|
Metric
|
KRSA
|
|---|---|
Return on Assets (Normalized) | −41.33% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
KRSA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|b>>M?q | LOCK|&#z&d | $123B | |||
| Moderna Inc
MRNA
| LOCK|Br%%&zK | LOCK|?Z | $86B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!<lNGz$ | LOCK|JSKq | $78B | |||
| argenx SE ADR
ARGX
| LOCK|kYrp!@ | LOCK|SN | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|v?&BF& | LOCK|&Jh | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|K#!fs< | LOCK|&?Gn | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|mZPVnK< | LOCK|NPJvp | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|Z$&@VF | LOCK|LwK | $22B | |||
| Incyte Corp
INCY
| LOCK|@WXZR&? | LOCK|K<M | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|^WR?Hr | LOCK|@j$ | $14B |
United States